10-Q: Zomedica Corp. Reports Q2 2026 Results: Revenue Up, Margins Dip

Zomedica Corp. announced its Q2 2026 financial results, showing a significant increase in revenue driven by contract manufacturing and growth in key product lines, though gross profit margins experienced a slight decline.

Summary

• Zomedica Corp. reported Q2 2026 revenue of $9.51 million, a 37% increase from $6.96 million in Q2 2025.
• For the first six months of 2026, revenue reached $18.31 million, up 36% from $13.46 million in the same period of 2025.
• Gross profit for Q2 2026 was $6.04 million, with a gross profit margin of 64%, down from 67% in Q2 2025.
• Net loss for Q2 2026 was $3.77 million, an improvement from a net loss of $7.40 million in Q2 2025.
• The company's cash and cash equivalents stood at $7.19 million as of June 30, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as cautiously optimistic, with revenue growth present but offset by a decrease in gross profit margin and continued net losses. The company is managing expenses well, but the overall financial picture remains challenging.

Positives

• Revenue increased by 37% for the three months ended June 30, 2026, reaching $9.51 million.
• Revenue for the six months ended June 30, 2026, increased by 36% to $18.31 million.
• Net loss for the three months ended June 30, 2026, decreased by 49% to $3.77 million.
• General and administrative expenses decreased by 13% for both the three and six-month periods.
• Research and development expenses decreased by 43% and 41% for the three and six-month periods, respectively.
• Selling and marketing expenses decreased by 21% and 22% for the three and six-month periods, respectively.
• The company believes its existing cash, cash equivalents, and available-for-sale securities are sufficient to fund its expected short-term needs (next 12 months).

Negatives

• Gross profit margin decreased to 64% for Q2 2026 from 67% in Q2 2025.
• Gross profit margin decreased to 63% for the six months ended June 30, 2026, from 67% in the same period of 2025.
• The company continues to incur net losses, with a loss of $8.30 million for the six months ended June 30, 2026.
• Cash and cash equivalents decreased by 12% to $7.19 million as of June 30, 2026, from $8.13 million as of December 31, 2025.
• Cash used in operating activities was $7.81 million for the six months ended June 30, 2026.

Risks

• The company has incurred losses and negative cash flows from operations since its inception.
• The company has an accumulated deficit of $308,072 as of June 30, 2026.
• Future capital requirements depend on many factors including development and commercialization costs, manufacturing costs, marketing and sales expenses, and potential business development or M&A activity.
• The company's ability to realize anticipated revenue from Diagnostic instruments is dependent on current assumptions and forecasted models, and a 25% reduction in estimated annual placement revenues would increase the payback period from 3.37 years to 4.74 years.
• There is a risk of loss to the extent a customer returns capital and discontinues consumable or related service purchases for Diagnostic instruments.

Future Outlook

The company expects revenue to increase in subsequent periods due to increased sales, marketing, and commercialization efforts. Research and development expenses are anticipated to increase as they maintain and enhance current product lines and develop new products. Selling and marketing expenses are expected to increase in line with product expansion and growth in commercialization efforts. The company expects to continue recording net losses until revenue offsets operating expenses.

Management Comments

• Management believes the disclosures are adequate to present fair information when read in conjunction with the audited financial statements from the 2025 Form 10-K.
• Management believes its existing cash, cash equivalents, and available-for-sale securities are sufficient to fund its expected short-term needs (next 12 months).
• Management believes its existing cash resources will be sufficient to fund its expected operational requirements for the long-term period (beyond the next twelve months).

Industry Context

StockSavvy.ai notes that Zomedica operates in the veterinary health sector, a market that has shown resilience and growth, particularly in companion animal care. The company's diversification into development services, while leveraging manufacturing capabilities, is a strategic move to optimize assets. However, the competitive landscape requires continuous innovation and effective commercialization to achieve profitability.

Comparison to Industry Standards

• The company's gross profit margin of 63-64% for the six months and three months ended June 30, 2026, respectively, is slightly below the typical range for established medical device and consumables companies, which often aim for margins above 70%.
• The significant decrease in net loss for the six months ended June 30, 2026, compared to the prior year, is largely due to the absence of a substantial impairment charge recorded in 2025. This improvement in net loss is a positive step, but the company's overall profitability is still challenged by its accumulated deficit.
• The company's strategy of placing diagnostic capital equipment with customers who commit to purchasing consumables is a common model in the medical device industry, aiming to create recurring revenue streams. However, the payback period and realization of anticipated revenue are critical metrics to monitor, as highlighted by the sensitivity analysis provided.

Legal Proceedings

• As of June 30, 2026, and continuing as of August 5, 2026, the Company is not aware of any pending or threatened material litigation claims against the Company.

Stakeholder Impact

• Shareholders may experience dilution if the company raises additional funds by issuing equity securities.
• Creditors may face increased debt service obligations if the company incurs indebtedness, potentially with restrictive covenants.
• Employees will continue to be compensated through salaries, wages, and stock-based compensation, with ongoing R&D and commercialization efforts potentially leading to new opportunities.
• Customers will continue to have access to Zomedica's veterinary health products and development services.

Next Steps

• Continue increasing sales, marketing, and commercialization efforts to drive revenue growth.
• Maintain and enhance current product lines and develop new products.
• Increase selling and marketing expenses in line with product expansion and commercialization efforts.
• Continue to manage and potentially reduce operating expenses proportionally relative to sales.

Key Dates

Recommendation

Zomedica Corp. shows positive revenue growth and improved net loss, driven by cost management and increased sales. However, the declining gross profit margin, continued net losses, and substantial accumulated deficit indicate ongoing financial challenges. While the company has sufficient short-term liquidity, the long-term outlook requires sustained revenue growth and a path to profitability. Therefore, a 'hold' recommendation is appropriate, pending further evidence of margin improvement and consistent profitability.

Keywords

veterinary health, companion animals, diagnostics, therapeutic devices, development services, TRUFORMA, PulseVet, VETIGEL